NPM1 and acute myeloid leukemia: Promising exploratory efficacy in relapsed or refractory KMT2A-r and NPM1-mutated AML was recently reported from ongoing analyses for the oral single-agents bleximenib and enzomenib with CR/CRh rates of 48%, 63%, with both showing a beneficial safety profile.